{"id":"hum0194","version":1,"url":"https://humandbs.dbcls.jp/research/hum0194/v1","datePublished":"2020-05-11","versions":[{"version":1,"datePublished":"2020-05-11"}],"title":{"ja":"分子プロファイリングによる薬剤抵抗性機構の研究","en":"Molecular mechanisms of drug resistance in cancer"},"summary":{"aims":{"ja":"手術、放射線と並び重要ながんの治療法である薬物療法（化学療法剤、分子標的薬剤、免疫チェックポイント阻害剤）は、高い有効性を示す一方で、薬効の個人差や薬剤耐性も分かってきており、そのメカニズムを解明することがより効果的な新規治療法開発につながると期待される。本研究では、進行性肺がんを対象とし、薬物療法前・後の腫瘍組織の遺伝子解析により、治療抵抗性機構を明らかにすることを目的としている。","en":"To study the molecular mechanisms of drug resistance in lung cancer patients by using of their tumor cells"},"methods":{"ja":"がん研究会有明病院を受診された肺がん症例から摘出した組織（腫瘍組織）等より抽出したDNAやRNAを対象とした高速塩基配列解析装置用いた解析","en":"Target Capture Sequencing"},"targets":{"ja":"肺がん症例","en":"tumor tissues from ROS1-rearranged non-small cell lung cancer patients"},"url":{"ja":[{"url":"https://www.jfcr.or.jp/genome/news/6813.html","text":"https://www.jfcr.or.jp/genome/news/6813.html"}],"en":null}},"listingSummary":{"methods":{"ja":"配列決定","en":"Sequencing"},"targets":{"ja":"肺癌：2症例\n（日本人）","en":"2 lung adenocarcinomas\n(Japanese)"},"typeOfData":{"ja":"NGS\n（Target Capture）","en":"NGS\n(Target Capture)"}},"releaseNote":{"ja":"肺がん2症例の腫瘍組織から抽出したDNAを用いたTarget Capture Sequencing解析結果をbamファイルにて提供する。","en":"DNAs extracted from tumor tissues of 2 patients with lung cancer were used for a target capture sequencing analysis (bam files)."},"dataProviders":[{"name":{"ja":"片山 量平","en":"Ryohei Katayama"},"organization":{"name":{"ja":"公益財団法人がん研究会","en":"Japanese Foundation for Cancer Research"}}}],"researchProjects":[{"name":{"ja":"がん化学療法センター 基礎研究部","en":"Div of Exp Chemother, Cancer Chemotherapy Center"},"url":{"ja":[{"url":"https://www.jfcr.or.jp/chemotherapy/department/fundamental/index.html","text":"https://www.jfcr.or.jp/chemotherapy/department/fundamental/index.html"}],"en":[{"url":"https://www.jfcr.or.jp/english/chemotherapy/department/fundamental/index.html","text":"https://www.jfcr.or.jp/english/chemotherapy/department/fundamental/index.html"}]}}],"grants":[{"title":{"ja":"低頻度Driver Oncogene変異陽性肺がんの標的療法開発と耐性機構研究","en":"Drug resistance mechanisms and therapeutic strategies in rare driver oncogene positive cancers"},"agency":{"ja":"科学研究費助成事業 基盤研究（B）","en":"KAKENHI Grant-in-Aid for Scientific Research (B)"},"grantIds":["16H04715"]},{"title":{"ja":"肺がんにおける分子標的治療残存細胞の解析を通じた獲得耐性出現機構の解析","en":"Molecular mechanisms of drug tolerant persister cells emergence after molecular target therapy in lung cancer"},"agency":{"ja":"科学研究費助成事業 基盤研究（B）","en":"KAKENHI Grant-in-Aid for Scientific Research (B)"},"grantIds":["19H03524"]},{"title":{"ja":"キナーゼ融合型がん遺伝子を標的にした阻害薬に対する耐性化の機構解明と克服法の探索","en":"Molecular analysis of acquired resistance to targeted therapies and search for overcoming drugs"},"agency":{"ja":"科学研究費助成事業 基盤研究（A）","en":"KAKENHI Grant-in-Aid for Scientific Research (A)"},"grantIds":["15H02368"]},{"title":{"ja":"細胞間相互作用による細胞ダイバーシティー形成機構の解明と疾患治療への応用","en":"Integrated analysis and regulation of cellular diversity for disease treatment"},"agency":{"ja":"科学研究費助成事業 新学術領域研究（研究領域提案型）","en":"KAKENHI Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area)"},"grantIds":["17H06327"]},{"title":{"ja":"異分野先端技術融合による薬剤抵抗性を標的とした革新的複合治療戦略の開発","en":"Development of combined strategy for treatment of drug-insensitive cancers with advanced technologies in interdisciplinary research areas"},"agency":{"ja":"日本医療研究開発機構（AMED） 次世代がん医療創生研究事業（P-CREATE）","en":"Project for Cancer Research and Therapeutic Evolution (P-CREATE), Japan Agency for Medical Research and Development (AMED)"},"grantIds":["JP19cm0106203"]},{"title":{"ja":"免疫抑制性分子の分泌型バリアントを介した腫瘍免疫微小環境変化と新規治療標的探索","en":"Mechanisms of checkpoint inhibitor resistance through secretable immunosuppressive variants"},"agency":{"ja":"日本医療研究開発機構（AMED） 革新的がん医療実用化研究事業","en":"Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED)"},"grantIds":["JP19ck0106472"]}],"relatedPublications":[{"title":"The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models","doi":"https://doi.org/10.1038/s41467-019-11496-z","datasets":["JGAD000272"]}],"datasets":["JGAD000272"],"controlledAccessUsers":[{"principalInvestigator":{"ja":"中岡 博史","en":"Hirofumi Nakaoka"},"affiliation":{"ja":"腫瘍ゲノム研究部, 公益財団法人佐々木研究所","en":"Department of Cancer Genome Research, Sasaki Institute"},"country":{"ja":"日本","en":"Japan"},"researchTitle":{"ja":"肺がん遺伝子解析研究","en":"Genetic analysis of lung cancer"},"periodStart":"2022-08-17","periodEnd":"2026-07-23","datasets":["JGAD000272"]}]}